argenx SE (ARGX) Up 7.2% — Time to Pull the Trigger?
argenx SE (ARGX) delivered a standout session on Thursday, climbing 7.15% and adding $60.90 to close at $912.62 on the NASDAQ. The move was decisively bullish, with shares pushing higher throughout the day on the back of a strong earnings catalyst. At $912.62, the stock sits roughly 4.3% below its 52-week high of $953.58, reached on July 2, 2026 — a level that now looms as the next meaningful test for the bulls.
Volume came in at approximately 432,000 shares, running well above the 90-day average of roughly 333,000. The above-average turnover on a strong up day signals genuine investor conviction behind the move, not a thin-volume drift.
Why argenx SE Price is Moving Higher
argenx SE surged after reporting a Q2 earnings result that cleared the bar by a wide margin. Diluted EPS came in at $7.32 against the analyst consensus of $6.24 — a $1.08 beat — and nearly doubled the $3.74 posted in the same period a year ago, representing 95.7% year-over-year growth. Total operating income reached $1.542 billion, topping the $1.442 billion consensus estimate by $100 million and rising 59.4% from $967 million in Q2 2025. Those are not incremental beats — they are the kind of numbers that force a meaningful repricing of expectations.
The engine behind the results was VYVGART, which generated product sales of $1.516 billion in the quarter, up 60% from $949 million a year earlier. Adoption continued to accelerate across generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy, the two indications driving commercial momentum. Management also highlighted the U.S. expansion of VYVGART and VYVGART Hytrulo to all adult gMG serotypes — a label broadening that enlarges the addressable patient population and extends the commercial runway meaningfully beyond what was previously available. Profit reached $472 million, up 92.7% year over year from $245 million, while the operating margin expanded sharply to 32.0% from 20.8% — a structural shift in profitability, not a one-quarter anomaly.
Looking ahead, the balance sheet provides additional confidence. Cash and current financial assets stood at $5.2 billion as of the report date, up from $4.4 billion at year-end 2025, giving argenx the firepower to advance its pipeline without financial constraint. The next major catalyst on the calendar is topline data from the registrational ALKIVIA myositis study, expected in Q3 2026 — a readout that could expand VYVGART's franchise into another high-value autoimmune indication and add a fresh leg to the investment thesis if results are favorable.
What is the argenx SE Rating - Should I Buy?
Weiss Ratings assigns ARGX a C+ rating. The rating was upgraded on 7/6/2026. Current recommendation is Hold.
The upgrade reflects genuine underlying improvement, and today's earnings report makes it easy to understand why the trajectory is moving in the right direction. Revenue growth of 73.04% earns the Excellent Growth Index — a figure that reflects VYVGART's rapid commercial penetration across multiple autoimmune indications in a short window, the kind of top-line velocity that is rare even within the high-growth biopharma space. The Excellent Solvency Index complements this, consistent with the $5.2 billion cash and financial asset position reported as of the latest quarter — a fortress balance sheet for a company still in active expansion mode. The Good Efficiency Index and Good Total Return Index round out the picture, suggesting that operational discipline is improving alongside revenue scale, even as argenx continues to invest heavily in pipeline advancement.
Where the C+ rating stops short of a Buy is partly a function of valuation and volatility. A forward P/E of 60.97 reflects elevated market expectations that leave limited room for execution stumbles — and with topline pipeline readouts still pending, uncertainty around future earnings power remains real. The Fair Volatility Index is a candid acknowledgment that ARGX can move sharply in either direction, as today's 7% session and the stock's 52-week range of $563.08 to $953.58 both illustrate. Investors with shorter time horizons or lower risk tolerance should weigh that dynamic carefully.
Within the Health Care sector, argenx SE ranks ahead of several large-cap peers. AbbVie Inc. (ABBV, C), Merck & Co., Inc. (MRK, C), Thermo Fisher Scientific Inc. (TMO, C), and Pfizer Inc. (PFE, C) all carry straight C ratings, while Danaher Corporation (DHR, C-) trails further behind. That relative standing suggests ARGX is among the stronger names in the peer group on Weiss's composite framework, even if the Hold recommendation calls for patience rather than aggressive accumulation at current levels.
About argenx SE
argenx SE (ARGX) is a commercial-stage biopharmaceutical company headquartered in Amsterdam, the Netherlands, operating within the Health Care sector. The company's commercial foundation rests on its FcRn-targeting platform, which underpins VYVGART (efgartigimod alfa) and VYVGART Hytrulo — therapies approved for generalized myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy. These are serious, often debilitating autoimmune conditions with historically limited treatment options, and argenx has established a meaningful commercial position across all three indications in the United States, Japan, China, and international markets.
Beyond the approved franchise, argenx maintains a deep pipeline built on the same FcRn biology and adjacent immune-modulating mechanisms. Efgartigimod is being studied across a broad set of additional indications including seronegative gMG, ocular myasthenia gravis, Graves' disease, myositis, Sjögren's disease, and systemic sclerosis. Empasiprubart targets multifocal motor neuropathy and CIDP, while adimanebart is in development for congenital myasthenic syndrome and spinal muscular atrophy. The pipeline breadth reflects a deliberate strategy of leveraging the same mechanistic expertise across multiple autoimmune diseases rather than building a single-asset profile.
Strategic partnerships strengthen argenx's competitive position. The company works with Zai Lab for efgartigimod development and commercialization, with Halozyme Therapeutics for its ENHANZE subcutaneous delivery technology — the backbone of VYVGART Hytrulo's formulation — and with AbbVie for ARGX-115. These collaborations provide geographic reach, formulation capability, and financial validation from established industry players, reinforcing the credibility of argenx's science and the commercial scalability of its platform.
Investor Outlook
argenx SE (ARGX) carries a Weiss Rating of C+ (Hold), reflecting a business with genuine momentum and a commercial franchise that is clearly gaining traction, balanced against a valuation that demands continued execution. Investors should watch the Q3 2026 topline readout from the ALKIVIA myositis study as the next inflection point — a positive result would expand the VYVGART franchise and likely test the stock's 52-week high of $953.58. See full rankings of all C+-rated Health Care stocks inside the Weiss Stock Screener.
--